[Skip to Content]
[Skip to Content Landing]
Other Articles
September 8, 1951


Author Affiliations

Cleveland; Des Moines, Ia.; Tulsa, Okla.

From Cleveland Clinic Hospital and the Frank E. Bunt Educational Institute.

JAMA. 1951;147(2):106-110. doi:10.1001/jama.1951.03670190006002

This article is based on a study of patients treated for hyperthyroidism with propylthiouracil and is concerned chiefly with the ability of such treatment to produce remissions. It also deals with certain advantages and disadvantages related to the over-all clinical handling of the disease by this method. The final decision as to the permanency of remissions would imply following each patient throughout his life. The patients discussed here have almost all been followed for 24 months or less.

The patients studied started treatment between January, 1946, and April, 1947. A total of 179 such hyperthyroid patients were followed. During the same interval of time, 71 additional patients were treated with propylthiouracil, but they could not be included in this survey for various reasons; they were patients who were undergoing trial therapy of arterial hypertension; patients with angina pectoris or congestive failure without hyperthyroidism, and patients who were observed only once